Section 3 of 6
Product information and disease description
408 evidence topics · 183 sources
Product description
Phase of product development
Summary: development and regulatory status as of October 2026
The FDA approved a supplemental new drug application (NDA 219132, supplement 2) for levacetylleucine (Aqneursa) for oral suspension on 18 September 2026 for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing at least 15 kg. The approval was granted to IntraBio Inc., and the FDA describes Aqneursa as the first treatment approved for ataxia in patients with A-T. The supplement was dated and received on 19 March 2026. IntraBio announced in May 2026 that the FDA had accepted it with priority review and a PDUFA target action date of 19 September 2026. Levacetylleucine has held orphan drug designation for A-T since 2 October 2018, and the FDA orphan drug record lists the exclusivity end date for the A-T approval as "TBD". Efficacy was evaluated in one randomized, double-blind, placebo-controlled, two-period crossover study of 73 participants (Trial 2, NCT06673056). IntraBio stated in its approval announcement that the product was commercially available. Levacetylleucine was first approved on 24 September 2024 for neurological manifestations of Niemann-Pick disease type C (NPC) with priority review, fast track, orphan drug, and rare pediatric disease designations, and a rare pediatric disease priority review voucher was granted with that approval. The Orange Book lists new chemical entity exclusivity through 24 September 2029, orphan drug exclusivity for the NPC indication through 24 September 2031, and four patents expiring 19 April 2037, one of which (patent 12144792, use code U-4603, submitted 23 September 2026) carries a use code for A-T. In the European Union, Aqneursa was authorised for NPC on 19 January 2026. IntraBio announced a variation application for A-T in June 2026, and the draft agenda of the CHMP meeting of 14 to 17 September 2026 lists the extension of indication for adoption. Acetylleucine has held European Union orphan designation for A-T since 11 January 2019.
Regulatory status: Approved; sNDA submitted March 2026 and approved September 2026
| Action date | Submission | Supplement categories or approval type |
|---|---|---|
| “09/18/2026” | “SUPPL-2” | “Efficacy-New Indication” |
Launch: Commercially available at approval in September 2026
| Field | Quoted record |
|---|---|
| Marketing approval date | “09/18/2026” |
| Approved labeled indication | “treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing > or = 15 kg” |
FDA approval on 18 September 2026
Evidence supporting approval
Supplemental application timeline: topline results and planned submissions
Supplemental application timeline: sNDA submission
Supplemental application timeline: FDA acceptance and priority review
Expedited programs: priority review and orphan drug designation for A-T
Special FDA designations: orphan drug designation for A-T
| Field | Quoted record |
|---|---|
| Generic name | “levacetylleucine” |
| Trade name | “Aqneursa” |
| Date designated | “10/02/2018” |
| Orphan designation | “Treatment of Ataxia Telangiectasia” |
| Orphan designation status | “Designated/Approved” |
| Sponsor | “IntraBio Inc.” |
| Marketing approval date | “09/18/2026” |
| Exclusivity end date | “TBD” |
Exclusivity listed in the Orange Book
| Exclusivity code | Exclusivity expiration |
|---|---|
| “NCE” | “09/24/2029” |
| “ODE-498” | “09/24/2031” |
Patents listed in the Orange Book
| Patent number | Patent expiration | Patent use code | Submission date |
|---|---|---|---|
| “11400067” | “04/19/2037” | “U-4170” | “04/22/2025” |
| “12144792” | “04/19/2037” | “U-4603” | “09/23/2026” |
| “12433862” | “04/19/2037” | “U-4284” | “10/22/2025” |
| “12433863” | “04/19/2037” | “U-4285” | “10/22/2025” |
Patent listing requirement for the supplement
Product history: first FDA approval for Niemann-Pick disease type C in 2024
| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
|---|---|---|---|---|
| “09/24/2024” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |
Product history: rare pediatric disease priority review voucher granted with the 2024 approval
Product history: advisory committee for the original application
Pivotal trial enrollment milestone
Regulatory status outside the United States: European Union authorisation for Niemann-Pick disease type C
| Field | Quoted record |
|---|---|
| EMA product number | “EMEA/H/C/006327” |
| Marketing authorisation holder | “Intrabio Ireland Limited” |
| Opinion adopted | “13/11/2025” |
| Marketing authorisation issued | “19/01/2026” |
Regulatory status outside the United States: European Union orphan designation for A-T
Regulatory status outside the United States: variation application to the EMA for A-T
Regulatory status outside the United States: scope of the European Union variation under CHMP review
Regulatory status outside the United States: extensions of indication recommended at the September 2026 CHMP meeting
Product information
Generic, brand name and therapeutic class of product
Generic name
“AQNEURSA® (levacetylleucine) for oral suspension” (opens the prescribing information at this quote)
| Drug name | Active ingredients | Strength | Dosage form/route | Marketing status |
|---|---|---|---|---|
| “AQNEURSA” | “LEVACETYLLEUCINE” | “1GM/PACKET” | “FOR SUSPENSION;ORAL” | “Prescription” |
Manufacturer: IntraBio
Development code and synonyms
“We evaluated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, for the treatment of Niemann-Pick disease type C.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Field | Quoted record |
|---|---|
| Name of medicine | “Aqneursa” |
| Active substance | “L-acetylleucine” |
| International non-proprietary name (INN) or common name | “L-acetylleucine” |
Therapeutic class: modified amino acid
Chemical description
Enantiomer: distinction from N-acetyl-DL-leucine and N-acetyl-D-leucine
Dosage forms and strengths
Granules for oral suspension: strength and appearance
Packet contents and inactive ingredients
Package and national drug code
| Package | Contents | NDC |
|---|---|---|
| Carton | “Carton containing 28 unit-dose packets” | “83853-101-01” |
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
- Price basis: wholesale acquisition cost (WAC) of $14,526 per carton of 28 one-gram packets on 1 January 2026, as reported by IntraBio to the Texas Department of State Health Services, which is $518.79 per packet ($14,526 ÷ 28). The A-T indication uses the 1 gram packet marketed for Niemann-Pick disease type C since 2024, whose WAC was $13,450 per carton at introduction on 24 September 2024 and $13,450 on 1 January 2025; the January 2026 price is 8.0% higher. The New York State Medicaid maximum reimbursable amount of $555.71428 per packet ($15,560 per carton of 28) is 7.1% above the January 2026 WAC, and no state filing or company statement identified gives a WAC after 1 January 2026.
- Dosing basis: dosage by actual body weight in 1 gram packets per the prescribing information, 2 grams per day (1 gram morning and evening) at 15 kg to less than 25 kg, 3 grams per day (1 gram morning, afternoon, and evening) at 25 kg to less than 35 kg, and 4 grams per day (2 grams morning, 1 gram afternoon, 1 gram evening) at 35 kg or more. Each dose is one or two whole packets, so cost is calculated per packet used.
- Base case: 4 grams per day at 35 kg or more, the weight band of 38 of 73 participants (52%) in the pivotal trial. $518.79 per packet × 4 packets per day × 365 days = $757,427 per year; ÷ 12 = $63,119 per month.
- Range: $378,714 per year ($31,559 per month) at 2 grams per day, $568,070 per year ($47,339 per month) at 3 grams per day, and $757,427 per year ($63,119 per month) at 4 grams per day. At the New York Medicaid amount per packet, the 4 grams per day cost is $811,343 per year ($67,612 per month).
- Rationale for the range: the label sets the daily dose by three body weight bands, and 18 of 73 trial participants (25%) weighed 15 kg to less than 25 kg and 17 (23%) weighed 25 kg to less than 35 kg; the label gives no dose reduction, titration, or renal or hepatic adjustment, and the price is the same per gram at every dose because one packet strength is marketed.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Wholesale acquisition cost at U.S. introduction: manufacturer filing with the California Department of Health Care Access and Information
| Field | Quoted record |
|---|---|
| Manufacturer name | “Intrabio Inc.” |
| National drug code | “83853010101” |
| Drug product description | “Aqneursa (levacetylleucine) 1 gram sachet, carton of 28” |
| Date introduced to market | “2024-09-24” |
| Wholesale acquisition cost at introduction (USD) | “13450.0000” |
Wholesale acquisition cost on 1 January 2026: manufacturer report to the Texas Department of State Health Services
| Field | Quoted record |
|---|---|
| Manufacturer name | “Intrabio, Inc.” |
| Drug trade name | “Aqneursa” |
| Drug generic name | “Levacetylleucine” |
| Wholesale acquisition cost on 1 January 2026 (USD) | “14526” |
Wholesale acquisition cost on 1 January 2025: manufacturer report to the Texas Department of State Health Services
| Field | Quoted record |
|---|---|
| Manufacturer name | “IntraBio Inc.” |
| Drug trade name | “Aqneursa” |
| National drug code | “83853010101” |
| Wholesale acquisition cost on 1 January 2025 (USD) | “13450” |
Cost per packet and cost at the maximum labeled dose: Oklahoma Medicaid review, February 2025
| Product | Cost per unit | Cost per 30 days | Cost per year |
|---|---|---|---|
| Aqneursa (levacetylleucine) 1 g packet | “$480.36” | “$57,643.20” | “$691,718.40” |
Estimated wholesale acquisition cost per 28 days: pharmacy benefit manager summary, fourth quarter 2024
| Product | Estimated wholesale acquisition cost (WAC) |
|---|---|
| Aqneursa (levacetylleucine) | “$40K per 28 days” |
Company price disclosure at the 2024 launch
Federal Supply Schedule and Big Four prices per carton of 28 packets
| Price type | Quoted trade name | Quoted package | Quoted price (USD) | Quoted price start date | Quoted price stop date |
|---|---|---|---|---|---|
| Federal Supply Schedule | “AQNEURSA 1GM/PKT GRANULES” | “28” | “13339.54” | “01/01/2026” | “06/30/2030” |
| Big Four | “AQNEURSA 1GM/PKT GRANULES” | “28” | “10206.02” | “01/01/2026” | “06/30/2030” |
New York Medicaid maximum reimbursable amount per packet: list effective 29 September 2026
| Field | Quoted record |
|---|---|
| Description | “AQNEURSA 1 GRAM GRANULE PACKET” |
| National drug code | “83853-0101-01” |
| Maximum reimbursable amount cost | “555.7142800” |
| Basis of maximum reimbursable amount | “EA” |
| Effective date | “09/29/2026” |
| Maximum quantity | “112.000” |
Reported cost at the time of the ataxia-telangiectasia approval: Fierce Pharma, September 2026
Pharmacy cash price per carton of 28 packets
Wholesale acquisition cost announced with the ataxia-telangiectasia approval
No evidence found.
Annual cost by body weight band
No evidence found.
National Average Drug Acquisition Cost
No evidence found.
Average sales price
Not applicable.
American hospital formulary service (AHFS), or other drug classification
ATC classification: WHO index
| ATC level | Code | Name |
|---|---|---|
| Anatomical main group | “N” | “NERVOUS SYSTEM” |
| Therapeutic subgroup | “N07” | “OTHER NERVOUS SYSTEM DRUGS” |
| Chemical subgroup | “N07XX” | “Other nervous system drugs” |
| Chemical substance | “N07XX27” | “levacetylleucine” |
ATC classification: European Medicines Agency record
| Field | Quoted record |
|---|---|
| Anatomical therapeutic chemical (ATC) code | “N07XX27” |
| Pharmacotherapeutic group | “Other nervous system drugs” |
FDA pharmacologic class indexing
| Field | Quoted record |
|---|---|
| Product NDC | “83853-101” |
| Pharmacologic class | “Bile Salt Export Pump Inhibitors [MoA]” |
| Pharmacologic class | “Breast Cancer Resistance Protein Inhibitors [MoA]” |
| Pharmacologic class | “Organic Anion Transporter 1 Inhibitors [MoA]” |
| Pharmacologic class | “Organic Anion Transporter 3 Inhibitors [MoA]” |
| Pharmacologic class | “P-Glycoprotein Inhibitors [MoA]” |
Indication
U.S. indication: ataxia in ataxia-telangiectasia
U.S. indication: signs and symptoms that ataxia comprises
European Union therapeutic indication and status of the A-T extension
Pharmacology
Mechanism of action
Molecular target: prescribing information
Mechanism as described by the European regulator
Proposed mechanism stated by the investigators of the A-T phase 3 trial
Rationale in A-T: mitochondrial and metabolic function
“The increasingly recognized role of ATM in oxidative stress was also considered and how it was pertinent to mitochondrial dysfunction, metabolic abnormalities and energy metabolism in A-T.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An important contribution to the meeting was the description of pathways /mechanisms that have led to the development of therapeutic approaches for A-T including the use of specific antisense oligonucleotides to restore ATM function in patients; delivery of full-length ATM cDNA to A-T cells; eDSP (formerly EryDex) that encapsulates dexamethasone sodium phosphate in a patient's own red blood cells and the use of small molecules (triheptanoin, nicotinamide riboside and N-acetyl leucine) to correct mitochondrial and metabolic function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Shared neurological manifestations as the basis for one development protocol across NPC, GM2 gangliosidoses, and A-T
“Despite their different etiologies, NPC, GM2, and A-T are all characterized by progressive neurodegeneration of the cerebellum and cerebrum, resulting in physical and cognitive decline, and premature death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Owing to their common neurological manifestations, and the mechanism of action of the investigational product N-acetyl-l-leucine, a single master protocol has been developed for the three disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cellular uptake: acetylation switches transport from LAT1 to MCT1 and organic anion transporters
“Here we show that acetylation of leucine switches its uptake into cells from the l-type amino acid transporter (LAT1) used by leucine to organic anion transporters (OAT1 and OAT3) and the monocarboxylate transporter type 1 (MCT1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both the kinetics of MCT1 (lower affinity compared to LAT1) and the ubiquitous tissue expression of MCT1 make it well suited for uptake and distribution of N-acetyl-l-leucine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MCT1-mediated uptake of a N-acetyl-l-leucine as a prodrug of leucine bypasses LAT1, the rate-limiting step in activation of leucine-mediated signalling and metabolic process inside cells such as mTOR.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our calculations show that at physiological pH, l-leucine is a zwitterion, whereas N-acetyl-l-leucine is present as mainly an anion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found that N-acetyl-l-leucine was a substrate of MCT1 with a Km of 3.0 mM (Fig. 4a) and an inhibitor of MCT1 (Fig. 4c) with an IC50 of 15 mM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transport of the D-enantiomer by the same carrier
“N-acetyl-D-leucine was also a substrate, with Km of 1.0 mM (Fig. 4b), and an inhibitor of MCT1 with an IC50 of 11 mM (Fig. 4d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which yielded an affinity (Ki) of 4.3 mM for the l-enantiomer and 1.6 mM for the d-enantiomer, similar to the respective Km values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This enantiomeric selectivity during transport by MCT1 provides a mechanistic explanation for the lower bioavailability of the l-enantiomer when administered as a racemate which impacts its therapeutic efficacy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prodrug hypothesis: intracellular deacetylation to L-leucine
“are consistent with N-acetyl-l-leucine acting as prodrug, such as l-dopa, in which both uptake and metabolism are crucial components of its mechanism of action” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MCT1 can deliver leucine via the prodrug form N-acetyl-l-leucine without interference from, and disruption to, the uptake of other essential amino acids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MCT1-dependent uptake in human induced neurons
“We demonstrated that NALL exhibits neuroprotective properties in MS- and HC-derived hiPNs subjected to acute damage induced by the microtubule-destabilizing agent nocodazole determined by neurite length. This effect can be blocked by inhibition of transporter-specific NALL uptake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The specific uptake of NALL via MCT1 as here firstly demonstrated in hiPNs suggests that the proposed transporter switch is functionally relevant in neurons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lysosomal regulation through transcription factor EB
“Here, we describe a direct effect of levacetylleucine on lysosomal regulation through modulation of TFEB, the master transcription factor for lysosomal and autophagy genes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In wild-type HeLa cells, levacetylleucine promotes TFEB activation and nuclear localisation. However, in NPC1 disease models, where we show that TFEB is over-activated and enriched in the nucleus due to lysosomal stress, levacetylleucine reduces nuclear TFEB and restores a more normal cytoplasmic-to-nuclear balance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of the drug are stereospecific: while the L-enantiomer is active, the D-enantiomer and racemate show no effect, revealing the antagonistic properties of the D-enantiomer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanisms summarized in a published review
Pharmacodynamics
Clinical pharmacodynamics: prescribing information
Clinical pharmacology and exposure-response: European assessment
Cardiac electrophysiology
Respiratory and central nervous system safety pharmacology
Active enantiomer: postural compensation and cerebellar glucose metabolism in the rat
“A significant reduction of postural imbalance scores was identified on day 7 in the N-acetyl-DL-leucine (p < 0.03) and the N-acetyl-L-leucine groups (p < 0.01), compared to the sham treatment group, but not in the N-acetyl-D-leucine group (comparison for applied dose of 24 mg i.v. per rat, equivalent to 60 mg/kg body weight, in each group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effect of N-acetyl-L-leucine on postural compensation depended on the dose: in contrast to 60 mg/kg, doses of 15 mg/kg and 3.75 mg/kg had no significant effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Measurements of the regional cerebral glucose metabolism (rCGM) by means of μPET revealed that only N-acetyl-L-leucine but not N-acetyl-D-leucine caused a significant increase of rCGM in the vestibulocerebellum and a decrease in the posterolateral thalamus and subthalamic region on days 3 and 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active enantiomer: vestibular compensation in the cat
“Whatever the parameters tested, the behavioral recovery was strongly and significantly accelerated under pharmacological treatments with N-acetyl-dl-leucine and N-acetyl-L-leucine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the N-acetyl-D-leucine isomer had no effect at all on the behavioral recovery, and animals of this group showed the same recovery profile as those receiving a placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neuronal membrane potential: central vestibular neurons of the guinea pig
“However, intracellular recordings from MVN neurons revealed that the nature of the response depended on the resting membrane potential.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, our results suggest that acetyl-DL-leucine might act mainly on abnormally hyperpolarized and/or depolarized MVN neurons, by bringing back their membrane potential towards a mean value of -65 to -60 mV.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease progression, survival, and glucose metabolism in Npc1-deficient mice
“When acetyl-dl-leucine and acetyl-l-leucine were administered pre-symptomatically to Npc1−/− mice, both treatments delayed disease progression and extended life span, whereas acetyl-d-leucine did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to untreated Npc1−/− mice, the life span of animals treated from weaning was modestly but significantly increased by 8 days (9.1%) with ALL treatment (P = 0.0334), 4 days with ADLL (P = 0.0305) (4.5%) and was not changed with ADL (P = 0.6908) (Fig. 1G), therefore displaying l-enantiomer selectivity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altered glucose and antioxidant metabolism were implicated as one of the potential mechanisms of action of the l-enantiomer in Npc1−/− mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individual enantiomers had distinct effects in NPC1 cerebellum; while ALL normalizes altered levels of PDH and LDH and mildly reduces SOD1 levels, ADL enhanced levels of the mitochondrial reactive oxygen species scavenger SOD2 (manganese dependent SOD2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory appraisal of the nonclinical pharmacology package
Glucose and glutamate metabolism and autophagy in a Sandhoff disease mouse model
“ADLL produced a modest but significant increase in life span, accompanied by improved motor function and reduced glycosphingolipid (GSL) storage in the forebrain and cerebellum, in particular GA2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ADLL was also found to normalize altered glucose and glutamate metabolism, as well as increasing autophagy and the reactive oxygen species (ROS) scavenger, superoxide dismutase (SOD1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autophagy flux and neuroinflammation after traumatic brain injury in mice
“We demonstrate that orally administered N-acetyl-l-leucine (NALL) significantly improved motor and cognitive outcomes in the injured mice, led to the attenuation of cell death, and reduced the expression of neuroinflammatory markers after controlled cortical impact (CCI) induced experimental TBI in mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our data indicate that partial restoration of autophagy flux mediated by NALL may account for the positive effect of treatment in the injured mouse brain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lysosomal, mitochondrial, and synaptic proteins in human dopaminergic neurons
Cerebral glucose metabolism in patients with cerebellar ataxia treated with the racemate
“Retrospective analyses of [18F]-FDG-PET data in 22 patients with CA (with vestibular and ocular motor disturbances) of different etiologies who were scanned before (PET A) and on AL treatment (PET B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With AL (PET B vs. A) cerebellar hypometabolism was deepened and sensorimotor hypermetabolism increased only in responders with clinical benefit, but not for the non-responders and the whole CA group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The enhanced divergence of cortical sensorimotor up- and cerebellar downregulation with AL in responders could reflect amplification of inhibitory cerebellar mechanisms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Pharmacokinetic parameters at steady state: prescribing information
Covariates: age, sex, race, and body weight
Pharmacokinetics: European summary of product characteristics
Clinical pharmacology program
Rich sampling in the phase 2 NPC study
Protein binding, bioavailability, metabolism, and excretion
Population pharmacokinetic analysis
Variability and reliability of pharmacokinetic sampling
Enantiomer pharmacokinetics after oral dosing in mice
“When administered as the racemate, both the maximum plasma concentration (Cmax) and the area under the plasma drug concentration over time curve (AUC) were much greater for the D-enantiomer relative to the L-enantiomer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When administered as the racemate, the ratio of D/L enantiomer was about 25 for both Cmax (Fig 5H; 26 versus 1, p = 0.014) and AUC (Fig 5I, 25 vs 1, p = 0.015).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elimination (ke and T1/2) was similar for both enantiomers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results are most readily explained by inhibition of uptake at an intestinal carrier of the L-enantiomer by the D-enantiomer, and by first-pass metabolism of the L-, but not D-enantiomer, likely by deacetylation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In brain and muscle, N-acetyl-L-leucine levels were lower than N-acetyl-D-leucine, consistent with rapid conversion into L-leucine and utilization by normal leucine metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deacetylation in human and mouse liver fractions
“The time course revealed that the disappearance of 1 µM N-acetyl-dl-[2H10]leucine asymptotically approached 50% of the initial concentration (i.e., 0.5 µM) and correlated well with the appearance of l-leucine for both human (Fig. 4f) and mouse (Fig. 4g) fractions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kinetic data fit to the Michaelis–Menten equation yielded a Km values of 216 and 69 µM and Vmax values of 6.8 and 2.6 µmol/min/mg protein for human and mouse, respectively (Fig. 4h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Brain distribution of the radiolabeled racemate in monkeys
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Warning: embryo-fetal toxicity
Interpretation of adverse reaction rates from clinical trials
Adverse reactions in A-T: safety population and exposure in Trial 2
Laboratory findings in A-T: thrombocytopenia in Trial 2
Adverse reactions in NPC: safety population and exposure in Trial 1
Rosacea and thrombocytopenia in NPC Trial 1
Safety information in the FDA approval announcement
Adverse events in the published report of the A-T phase 3 trial
Patient counseling
Nonclinical toxicology: carcinogenesis, mutagenesis, and impairment of fertility
Carcinogenicity study commitment and repeat-dose toxicology: European assessment
European Union contraindication and hypersensitivity warning
European Union excipient warning: isomalt and hereditary fructose intolerance
European Union adverse reaction listing and overdose
Pooled NPC safety database: European assessment
Liver enzymes and the European risk management plan
Special populations
Pregnancy: risk summary
Pregnancy: animal data
Pregnancy: European Union labeling
Lactation
Females and males of reproductive potential
Pediatric use in A-T and the 15 kg weight limit
Pediatric use in NPC and supporting pharmacokinetic data
Pediatric limits in the European Union: 6 years and 20 kg
Geriatric use
Age and sex subgroups in the pooled NPC safety data
Drug/Drug, drug/disease interactions
Effects of other drugs on levacetylleucine
N-acetyl-DL-leucine and N-acetyl-D-leucine
Nonclinical basis of the enantiomer interaction
“Second, when administered as purified N-acetyl-L-leucine, both the Cmax and the AUC for N-acetyl-L-leucine were higher compared to administration as the racemate, even when scaled for the relative dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Levacetylleucine as a transporter substrate
Enzyme modulators and absence of clinical interaction studies
Effects of levacetylleucine on other drugs
P-glycoprotein transporter substrates
In vitro enzyme and transporter studies: prescribing information
| Study | Prescribing information |
|---|---|
| Cytochrome P450 inhibition and induction | “Levacetylleucine does not inhibit CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 and does not induce CYP 1A2, 2B6, or 3A4.” |
| Transporter inhibition | “Levacetylleucine inhibits P-gp, BCRP, bile salt export pump (BSEP), OAT1 and OAT3, but does not inhibit organic anion transporting polypeptide (OATP)1B1 and OATP1B3.” |
Substrates of P-gp, BCRP, BSEP, and MATE transporters: European Union labeling
Inhibitory concentrations and the planned clinical interaction study
Cytochrome P450 substrates: European assessment
Dosing and administration
Dosage
Basis of the dosage and packet strength
Pregnancy status before treatment initiation
Dose rationale: European assessment
Administration
Oral administration: preparation of the suspension
Gastrostomy tube administration
Administration with respect to food: European Union labeling and planned food effect study
European Union administration: dispersion in water and gastrostomy tube size
Dispersion of two packets at once: outstanding quality recommendation
Access and distribution
Specialty pharmacy: Curant Health
Home delivery and retail pharmacy availability
Patient support program: AQNEURSA Cares
AQNEURSA Cares services initiated by the enrollment packet
| Service | Website text |
|---|---|
| Benefits verification | “Verification of insurance coverage for AQNEURSA” |
| Copay eligibility | “Determination of eligibility for co-pay assistance” |
| Prior authorization | “Support during the prior authorization process” |
| Shipment | “Patient outreach and scheduling of medication shipments directly to the patient/caregiver” |
Enrollment form: prescription fields and diagnosis codes
| Form item | Form text |
|---|---|
| Prescription | “AQNEURSA Prescription (NDC: 83853-101-01)” |
| Supply | “Dose & Directions (28-Day Supply)” |
| Diagnosis code for A-T | “G11.3 Ataxia-telangiectasia” |
| Diagnosis code for NPC | “E75.242 Niemann-Pick Disease Type C” |
| Body weight | “Patient weight” |
| Eligible prescribers and patients | “FOR U.S. PATIENTS AND U.S.-LICENSED PRESCRIBERS ONLY” |
Benefits verification and prior authorization support
Copay assistance and financial assistance
Prior authorization checklist: diagnosis code and diagnostic information for A-T
| Checklist item | Checklist text |
|---|---|
| ICD-10-CM diagnosis code | “G11.3 Ataxia-Telangiectasia (A-T)” |
| Official descriptor of the code | “Cerebellar ataxia with defective DNA repair” |
| Genetic confirmation | “Confirmation of A-T diagnosis by genetic testing identifying biallelic pathogenic variants in the ATM gene” |
| Biomarker | “Elevated serum alpha-fetoprotein (AFP)” |
| Clinical features | “Observation of the clinical features of A-T” |
| Systemic features | “oculocutaneous telangiectasia, immunodeficiency, pulmonary disease, endocrine abnormalities” |
Prior authorization checklist: patient condition and medical history
| Checklist item | Checklist text |
|---|---|
| Growth | “Patient weight, growth, and development” |
| Testing | “Neurological and/or psychological testing results” |
| Symptoms | “Symptoms and quality of life (physician observation)” |
| Records | “Chart notes” |
| Laboratory | “Laboratory test results” |
| Pregnancy | “Verification that the patient is not pregnant” |
| Hospitalization | “Details on hospital admissions and discharges” |
Prior authorization checklist: supporting materials and coverage disclaimer
Sample letters of medical necessity and appeal for A-T
Expanded access for A-T: manufacturer policy
Expanded access for A-T: registry record
Published payer policies that predate the A-T approval: Cigna Healthcare
| Policy item | Policy text |
|---|---|
| Coverage policy number | “IP0715” |
| Section heading | “Conditions Not Covered” |
| Listed condition | “Ataxia-Telangiectasia.” |
| Latest revision | “Annual Revision” |
| Summary of changes | “No criteria changes.” |
| Revision date | “12/15/2025” |
Published payer policies that predate the A-T approval: Medical Mutual
| Policy item | Policy text |
|---|---|
| Last revised date | “08/21/2025” |
| Section heading | “CONDITIONS NOT RECOMMENDED FOR APPROVAL” |
| Listed condition | “Ataxia-Telangiectasia.” |
| Stated basis | “Results are not yet available.” |
Published payer policies that predate the A-T approval: UnitedHealthcare
| Policy item | Policy text |
|---|---|
| Program number | “2026 P 2355-4” |
| Effective date | “4/1/2026” |
| Diagnosis criterion | “Diagnosis of Niemann-Pick disease type C (NPC)” |
| Authorization duration | “Authorization will be issued for 12 months.” |
Payer coverage policies with criteria for the A-T indication
No evidence found.
Co-prescribed/Concomitant therapies
N-acetyl-DL-leucine products
Conditions for other concomitant therapies in the pivotal A-T trial
Medications prohibited in the phase 2 master protocol that included A-T
Standard-of-care and supportive-care medication in clinical trials
Effect of levacetylleucine on quality measures
No evidence found.
Product comparison
Summary: levacetylleucine, intra-erythrocyte dexamethasone, and the racemate
- Levacetylleucine is supplied as an oral suspension in 1 gram packets and is given two or three times daily according to body weight. In Trial 2 of the prescribing information, 73 participants with A-T received levacetylleucine and placebo for 12 weeks each in a crossover design, and the least squares treatment effect on the functional SARA total score was -0.6 (95% CI -0.9 to -0.2). The FDA announcement describes Aqneursa as the first treatment approved for ataxia in A-T.
- Intra-erythrocyte dexamethasone sodium phosphate (eDSP, formerly EryDex) is given by intravenous infusion: once a month for 6 months in ATTeST, and six infusions every 21 to 30 days in NEAT. In ATTeST, 175 participants received treatment and the least squares mean differences from placebo in mICARS change were -1.37 for the low-dose group and -1.40 for the high-dose group; the primary endpoint was not met. NEAT randomized 105 participants, its primary endpoint did not reach statistical significance (p=0.0851), and the sponsor announced that it would cease clinical development of eDSP.
- N-acetyl-DL-leucine, the racemate marketed in France as Tanganil for acute vertigo, has been reported in A-T in a case series of 6 participants and in a single case report. In the ALCAT crossover trial of 108 participants with cerebellar ataxia of hereditary, nonhereditary, or unknown type, the mean treatment difference in SARA total score between the racemate and placebo was 0.23 points (95% CI -0.40 to 0.85).
- No head-to-head clinical comparison of levacetylleucine with the racemate has been performed. The CHMP concluded that the data submitted for the European application did not allow the conclusion that the two differ significantly in efficacy or safety.
Approved treatments for A-T before and at the approval of levacetylleucine
Treatments under investigation for A-T: narrative review
“Currently, there are no curative therapies available for this disorder.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This review provides an overview of the latest advances in treatment methods including 1- Acetyl-DL-leucine, 2- Bone Marrow Transplantation, 3- Gene Therapy, 4- Dexamethasone, and finally 5- Red Blood Cells (RBCs) as a carrier for dexamethasone (encapsulation of dexamethasone sodium phosphate into autologous erythrocytes, known as EryDex).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most of the treatments under investigation are in the early stages, except for the EryDex System.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Levacetylleucine: product profile from the prescribing information
Intra-erythrocyte dexamethasone sodium phosphate: product description
Intra-erythrocyte dexamethasone sodium phosphate: ATTeST phase 3 trial
Intra-erythrocyte dexamethasone sodium phosphate: NEAT phase 3 trial topline results
Racemate N-acetyl-DL-leucine in A-T: case series and case report
“There is no authorized treatment for ataxia telangiectasia (AT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Six patients were treated with ADLL 3 g/day for 1 week followed by 5g/day for 3 weeks to 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Scale for Assessment and Rating of Ataxia changed from the baseline, mean, (SD, min-max) of 22.1 (5.88, 11-28.5) to 18 points (5.39, 8.5-23.5) after 1 month on medication (P = .0028).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study assessed the effect of 16 weeks N-acetyl-DL-leucine supplementation on ataxia symptoms in a 9-year-old female with AT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The SARA score progressively improved, and by week 16 had improved by 11.0 points (48.88%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Racemate N-acetyl-DL-leucine in cerebellar ataxia: ALCAT randomized crossover trial
“In this randomized clinical crossover trial including 108 patients with cerebellar ataxia, a 6-week treatment with acetyl-DL-leucine was not effective. Adverse events were mild.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned (1:1) to receive acetyl-DL-leucine orally (5 g per day after 2 weeks up-titration) followed by a matched placebo, each for 6 weeks, separated by a 4-week washout, or vice versa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no evidence of a difference in the mean absolute change from baseline to week 6 in SARA total scores between both treatments (mean treatment difference: 0.23 points [95% CI, −0.40 to 0.85 points]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Levacetylleucine and the racemate: nonclinical differences
“Taken together, these results have clinical implications supporting the use of N-acetyl-L-leucine instead of the racemate or N-acetyl-D-leucine, and support the research and development of only N-acetyl-L-leucine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is concluded that the N-acetyl-L-leucine isomer is the active part of the racemate component since it induces a significant acceleration of the vestibular compensation process similar (and even better) to that observed under treatment with the racemate component only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remarkably, the racemate N-acetyl-D-L-leucine also failed to activate TFEB translocation, indicating that the presence of the D-enantiomer in the racemic mixture antagonises the effect of the pharmacologically active L-enantiomer, levacetylleucine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Levacetylleucine and the racemate: European regulatory appraisal
Place of product in therapy
Disease description
Definition and etiology
Clinical definition
“Ataxia telangiectasia (A-T) is an autosomal recessive disorder primarily characterized by cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility and radiation sensitivity. A-T is often referred to as a genome instability or DNA damage response syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A-T is a complex disorder with substantial variability in the severity of features between affected individuals, and at different ages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ATM gene and protein
“The mode of inheritance for A-T is autosomal recessive. A-T is caused by mutations in the ATM (ataxia telangiectasia, mutated) gene which was cloned by Savitsky et al. in 1995” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ATM is located on human chromosome 11q22-q23” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ATM gene encodes a large 3056 amino acid protein of the same name whose best known, and arguably most well understood, role is coordinating the cellular response to DNA DSBs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classic and variant forms
Genotype and residual ATM kinase activity
“To study genotype-phenotype correlations, we evaluated the clinical and laboratory data of 51 genetically proven A-T patients, and additionally measured ATM protein expression and kinase activity. Patients without ATM kinase activity showed the classical phenotype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Residual kinase activity correlated with a milder and essentially different neurological phenotype, absence of telangiectasia, normal endocrine and pulmonary function, normal immunoglobulins, significantly lower X-ray hypersensitivity in lymphocytes, and extended lifespan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The genotypes of severely affected patients generally included truncating mutations resulting in total absence of ATM kinase activity, while patients with milder phenotypes harbored at least one missense or splice site mutation resulting in expression of ATM with some kinase activity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Ataxia-telangiectasia
United States birth incidence: nationwide case finding
| Measure | Estimate |
|---|---|
| Cases identified in 1970 to 1972 and 1980 to 1984 | “231 white, 29 black, and three Oriental A-T cases”View highlighted excerpt for this quote |
| Birth rate of identified white patients, 1965 to 1969 | “3.0 per million live births”View highlighted excerpt for this quote |
| Highest observed state incidence (Michigan, 1965 to 1969) | “11.3 per million births”View highlighted excerpt for this quote |
United Kingdom birth frequency
“A prevalence study of ataxia telangiectasia was conducted in the West Midlands, with a population of over 5 million. The prevalence in those aged 50 or less was found to be 1 in 514,000 and the birth frequency to be about 1 in 300,000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Range of reported incidence
“The world-wide prevalence of A-T is estimated to be between 1 in 40,000 and 1 in 100,000 live births.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the exception of consanguineous populations, individuals of all races and ethnicities are affected equally by A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States estimate per live births
Prevalence of Ataxia-telangiectasia
Estimates stated by the manufacturer
Children known to the United States patient organization
Participants in the Global A-T Family Data Platform
“Between 2016 and 2024, 624 participants with ataxia telangiectasia completed the questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant ages ranged from 0 to 64 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: prevalence estimates and registry counts
“The Orphanet registry estimates the average prevalence of A-T at 1/100 000 children” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of patients with A-T in Europe is estimated to be 1/150 000” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Europe, 410 living A-T patients are currently listed on the European Society for Immunodeficiencies registry” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most reliable estimates for the number of people with A-T, in the UK at least, are 3 per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data of 659 A-T patients on age, gender, immunoglobulin levels IgA, IgG2, IgM, and lymphocyte counts, date of birth, and date of death (until 2014) were collected from the ESID registry and analyzed for mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom and Ireland: number of affected families and individuals
Carrier frequency
“Given that complementation analysis has demonstrated the genetic heterogeneity of A-T, the A-T heterozygote frequency will probably fall between 0.68% and 7.7%, with 2.8% being the most likely estimate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Founder populations with higher carrier frequency
| Population | Heterozygote frequency |
|---|---|
| Druze population in northern Israel | “One in three to one in 15” |
| Moroccan and Tunisian Jewish population | “One in 81” |
| Romani population in Spain | “One in 36” |
Rank among autosomal recessive hereditary cerebellar ataxias
Absence of population-based prevalence studies
“Despite our comprehensive literature search and review, we did not find population-based studies and were unable to determine the prevalence of A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite excluding duplicate cases, we found reports of 18247 cases. Most were classical A-T but 2.5% were reported as variants. The worldwide prevalence of variant A-T is not determined as yet.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although cases were reported from 74 countries, nearly a quarter of the cases were from the USA and another quarter from just four other countries (the UK, Italy, Germany, and Turkey).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Course of neurological decline in classic A-T
“In the classic presentation of the disease, ataxia first appears during the toddler stage when children begin to sit and walk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In primary school years, walking becomes more difficult, and children will use doorways and walls for support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of these neurologic problems stop progressing after the age of about 12–15 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological deficits are typically observed during the toddler years resulting in wheelchair dependency around the age of 10.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at symptom onset and at diagnosis
“Referral centers from 9 Latin American countries participated in this retrospective cohort study, and 218 patients were included. Median (IQR) ages at symptom onset and diagnosis were 1.0 (1.0-2.0) and 5.0 (3.0-8.0) years, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean age at which the first neurological symptom was noted was 1.8 ± 1.0 years. The mean age at diagnosis of ataxia telangiectasia was 3.95 ± 2.56 years, and the mean age at the time of walking capacity reporting was 7.97 ± 4.60 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loss of walking capacity: Global A-T Family Data Platform
“Children with ataxia telangiectasia who presented with neurological symptoms at 5 years of age or younger and were 18 years of age or younger at the time of walking capacity reporting were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean walking capacity scores from 372 participants remained stable until age 5, followed by progressive worsening between ages 5 and 14, with persistently high scores thereafter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the majority of patients reported walking independently all or most of the time (225/372, 60.5%); 72/372 (19.3%) reported needing assistance for walking, while 75/372 (20.2%) used a wheelchair.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean age at which wheelchair dependence developed was 13.5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We could not control for disease severity, as genetic confirmation and ATM kinase activity data were not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mean age by walking capacity category: Global A-T Family Data Platform
| Walking capacity category | Mean age and number of participants |
|---|---|
| Walks independently | “5.0 ± 2.7 years (N = 170)”View highlighted excerpt for this quote |
| Walks independently most of the time | “6.6 ± 3.5 years (N = 55)”View highlighted excerpt for this quote |
| Needs assistance for long trips | “10.3 ± 3.7 years (N = 62)”View highlighted excerpt for this quote |
| Walks with bilateral support | “10.1 ± 2.7 years (N = 10)”View highlighted excerpt for this quote |
| Uses wheelchair without assistance | “14.2 ± 2.5 (N = 9)”View highlighted excerpt for this quote |
| Uses wheelchair with assistance | “13.4 ± 3.2 (N = 66)”View highlighted excerpt for this quote |
Age at wheelchair use in national and referral cohorts
“The mean age of loss of walking was 10 years and of writing 8 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty one patients (34.1%) became dependent on wheelchair at a mean age of 12.1±2.8 years. Eleven patients (12.1%) became bedridden by a mean age of 14.7±1.8 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rate of change on the Scale for the Assessment and Rating of Ataxia in adults
“We analysed longitudinal Scale for the Assessment and Rating of Ataxia (SARA) data from the largest published adult AT cohort to date (n = 82, age > 16 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological impairment progressed with a mean SARA increase of 0.38 points/year. Adults with classic AT were more severely affected than those with variant AT, with SARA scores approximately 8-9 points higher at baseline. However, neurological progression in adulthood was similar between classic and variant AT (0.33 vs 0.41 points per year), which includes 15 individuals with the antisense oligonucleotide targetable c.5763-1050A>G variant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SARA remains a useful outcome measure but may underestimate progression in advanced disease and non-cerebellar domains.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA scores by disease form
“Ataxia was present in all patients except one (p13) and with increased severity in those with classical A-T as shown by a median SARA score of 30 for these 12 patients compared to a median score of nine for the two with vA-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SARA and A-T NEST score ranges by functional severity in variant A-T
Structure of SARA and its limitations in A-T
“It assesses 8 domains: gait, stance, sitting ability, speech disturbance, finger chase, nose-finger test, fast alternating hand movements and heel-shin slide. It carries a maximum score of 40 with higher scores indicating more severe ataxia symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the SARA score remains unvalidated specifically for use in A-T and is not without its limitations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many classical A-T patients lose ambulation by their teenage years, and it is unclear how this influences the assessment of disease progression in non-ambulant patients who continue to report clinical deterioration” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The medical records of 55 individuals (males = 27, females = 28) with genetically confirmed diagnoses of A-T who attended the National Adult A-T Clinic at Royal Papworth Hospital over a 7-year period were retrospectively reviewed in a longitudinal manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The A-T NEST correlates strongly with the SARA score at the single timepoint level and changes proportionally with the SARA score longitudinally which demonstrates its ability to track the severity of the disease over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even in advanced stages of A-T, the scores lose their value, since the course of the disease for patients who are already wheelchair-bound becomes gradually more difficult to quantify by an increase in points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The SARA score was available from 28 A-T patients and correlated significantly with NfL (r = 0.41, p ≤ 0.05)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
A-T Index and A-T NEST: relation to age and individual progression
“The overall index was applied to 52 patients with A-T, 2 to 29 years of age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a linear regression model of individuals under 19 years of age, controlled for correlation within sibships, age accounted for 87% of the variation in the A-T Index.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological assessments were performed using the A-T Index (Crawford Score) and the A-T Neurological Examination Scale Toolkit (A-T NEST).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike the per-genotype analysis, the individual progression of neurological scores in the 34 patients that attended on three or more occasions was not smooth and linear (and in some cases improved over time).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Residual kinase activity confers a milder phenotype but there is no difference between kinase-dead and protein-null genotypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
International Cooperative Ataxia Rating Scale scores in a pediatric cohort
“We recruited 63 patients with ataxia, aged 10.76 ± 3.2 years, followed at 6 international AT centers, 49 of them (77.8%) with classical AT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean ICARS score was 44.7 ± 20.52, and it's severity positively correlated with age (Spearman correlation, r = 0.46, p < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Median survival: United States cohorts
“In the prospective ATCC cohort, median survival is calculated to be 25 years (fig 1). In the retrospective ATCP cohort, median survival is 19 years (fig 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality crossed the 25th and 75th centiles in the prospective ATCC cohort at ages 18 and 28, and at ages 14 and 28 in the retrospective ATCP cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median date of death in the ATCP cohort was 1993, compared with the median date of death in the ATCC cohort of 2001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Life expectancy does not correlate well with severity of neurological impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causes of death: Johns Hopkins prospective cohort
“There were 24 deaths through the end of 2004.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“nine apparently died of complications of chemotherapy or cancer, seven of pneumonia, four had significant acute neurological deterioration associated with multiple CNS telangiectatic vascular abnormalities, two died from sudden unknown causes, and two died from complications of chronic lung disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence most deaths should be considered to be the result of a complication of ataxia telangiectasia rather than an inevitable consequence of severe neurological debilitation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival and risk factors for death: French national cohort
“We performed a retrospective cohort study in France of 240 patients with A-T born from 1954 to 2005 and analyzed ATM mutations in 184 patients, along with neurologic manifestations, infections, and cancers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with A-T, the Kaplan-Meier 20-year survival rate was 53.4%; the prognosis for these patients has not changed since 1954.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer (hazard ratio, 2.7; 95% CI, 1.6-4.5) and respiratory tract infections (hazard ratio, 2.3; 95% CI, 1.4-3.8) were independently associated with mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer (hazard ratio, 5.8; 95% CI, 2.9-11.6) was a major risk factor for mortality among patients with null mutations, whereas respiratory tract infections (hazard ratio, 4.1; 95% CI, 1.8-9.1) were the leading cause of death among patients with hypomorphic mutations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival: German single-center cohort
“Our study includes 69 A-T patients between 8 January 2002 and 1 December 2019.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 15-year OS of 82·5% (72-95%) was significantly decreased among A-T patients with malignancies, who had a median OS of 2·11 years, with a two-year-estimated OS of 50·7% (31-82%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival by phenotype and immunological status: Dutch cohort
“This retrospective cohort study of 61 AT patients shows that classical AT patients had a shorter survival than variant patients (HR 5.9, 95%CI 2.0-17.7), especially once a malignancy was diagnosed (HR 2.5, 95%CI 1.1-5.5, compared to classical AT patients without malignancy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with the hyper IgM phenotype with hypogammaglobulinemia (AT-HIGM) and patients with an IgG2 deficiency showed decreased survival compared to patients with normal IgG (HR 9.2, 95%CI 3.2-26.5) and patients with normal IgG2 levels (HR 7.8, 95%CI 1.7-36.2), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival, IgA deficiency, and causes of death: European Society for Immunodeficiencies registry
“As shown in Fig. 1, A-T patients with deficient IgA died significantly earlier than patients with no deficient IgA (p < 0.0001). The corresponding hazard ratio (HR) for patients with IgA deficiency compared to those with IgA-levels greater than 0.07 g/L was 1.9 (1.34–2.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data about the cause of death was available from 60 A-T patients with available IgA values in the ESID registry and the patients from the Frankfurt cohort (Fig. S2). Of these, 27 died from respiratory failure, 29 died from cancer, and 4 died for other reasons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths and causes of death: Italian Primary Immunodeficiency Network cohort
“Retrospective data of 69 AT patients diagnosed between December 1984 and November 2019 were collected from the database of the Italian Primary Immunodeficiency Network.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the end of the Fup, 11 patients were dead at a mean age ± SD of 22.4 ± 6.5 years. Causes of death were severe pneumonia (n = 6), pneumonia + malignancy (n = 2), and malignancy (n = 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at death and causes of death: systematic review of published cases
“687 cases reported 752 causes of death among which malignancy was the most frequently reported cause. Median (IQR, range) age of death (n = 294) was 14 years 0 months (10 years 0 months to 23 years 3 months, 1 year 3 months to 76 years 0 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As expected, median age of death was lower in classical cases (14 years 0 months) compared to variant cases (48 years 0 months), likely due to no ATM protein kinase activity resulting in a more severe phenotype in classical cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Predominance of case reports, and case series demonstrate the lack of robust evidence to determine the natural history of A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Course of variant A-T
“The study includes 57 individuals. Mean age at assessment was 37.5 years. Most had their first symptoms by age 10 (81%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease severity was mild in one third of patients, and 43% were still ambulant 20 years after disease onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Forty‐two individuals used a wheelchair and 15 were still ambulant. Median age at first getting a wheelchair was 20 years (range, 8–51; Fig 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classic A-T beyond 30 years of age
“In the Dutch cohort, seven classic A–T patients survived beyond 30 years of age. Fourteen additional patients were retrieved by the literature search.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients had pulmonary, endocrine, cardiovascular, and gastro-intestinal problems. All patients had a tetraparesis with contractures. This led to immobilization and frequent hospital admissions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Function of the ATM protein
“A-T is caused by mutations in the ATM (Ataxia Telangiectasia, Mutated) gene which encodes a protein of the same name. The primary role of the ATM protein is coordination of cellular signaling pathways in response to DNA double strand breaks, oxidative stress and other genotoxic stress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cerebellar degeneration and Purkinje cell loss
“The neuropathological hallmark of A-T is diffuse degeneration or atrophy of the cerebellar vermis and hemispheres, involving Purkinje cells (PCs) and, to a lesser extent, granule neurons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cause of this cell death is not known, though many hypotheses have been proposed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Much of the evidence in existence to date supports the idea that a defective response to genotoxic and/or oxidative stress contributes to the neuronal cell dysfunction and death in A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In parallel, ATM also functions in the maintenance of the cellular redox balance, mitochondrial function and turnover and many other metabolic circuits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This review suggests that it is the absence of a comprehensive role of ATM in responding to ongoing DNA damage induced mainly by endogenous agents. It is the ensuing deterioration and eventual loss of cerebellar Purkinje cells, which are very vulnerable to ATM absence due to a unique combination of physiological features, which kindles the cerebellar decay in A-T.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proposed mechanisms of neurodegeneration
Neurological involvement outside the cerebellum
“Various neuropathological abnormalities (e.g. neuronal changes, gliosis and vascular changes) have also been observed in the cerebrum, brain stem and spinal cord.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, the loss of cerebellar cells does not explain all of the neurologic abnormalities seen in people with A-T, and the effects of ATM deficiency on the other areas of the brain outside of the cerebellum are being actively investigated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuroimaging correlates of cerebellar degeneration
“For the majority of people with A-T, neuroimaging studies in the toddler years and early child years are normal” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As the disease progresses, MRI studies support the pathological finding of variable, progressive and diffuse cerebellar atrophy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum neurofilament light chain as a marker of neurodegeneration
“We found significantly increased levels of NfL in patients with A-T compared to healthy controls (21.5 ± 3.6 pg/mL vs. 9.3 ± 0.49 pg/mL, p ≤ 0.01). There was a significant correlation of NfL with age, AFP, and SARA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ATM functions outside the DNA damage response
“The pathogenesis of A-T is not limited to the role of ATM in the DNA damage response (DDR) pathway, and it has other functions mainly in the hematopoietic cells and neurons. ATM adjusts the functions of organelles such as mitochondria and peroxisomes and also regulates angiogenesis and glucose metabolisms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cellular phenotype and radiosensitivity
“Cells derived from patients with A-T demonstrate sensitivity to ionizing irradiation, chromosomal instability, shortened telomeres, premature senescence and a defective response to DNA double strand breaks (DSBs)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanisms of lung disease
“Immune dysregulation in A-T can lead to recurrent pneumonia, bronchiectasis and ILD. Poor mucociliary clearance from an inadequate cough and chronic aspiration from impaired bulbar function can increase severity of chronic respiratory symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unexplained alpha-fetoprotein elevation and telangiectasia
“Why the majority of individuals with A-T have elevated levels of AFP remains unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cause of telangiectasia or dilated, enlarged blood vessels in the absence of the ATM protein is not yet known.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Diagnostic criteria and genetic confirmation
“The diagnosis of A-T is usually suspected by the combination of neurologic clinical features (ataxia, abnormal control of eye movement, and postural instability) with one or more of the following which may vary in their appearance: telangiectasia, frequent sinopulmonary infections and specific laboratory abnormalities (e.g. IgA deficiency, lymphopenia especially affecting T lymphocytes and increased alpha-fetoprotein levels).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A diagnosis of A-T can be confirmed by the finding of an absence or deficiency of the ATM protein or its kinase activity in cultured cell lines, and/or identification of the pathological mutations in the ATM gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum alpha-fetoprotein
“We have followed 12 patients (five girls and seven boys) for 1-12 years (mean 5.5 years) measuring in each patient AFP 2-8 (mean 4) times. Serum AFP levels were increased in all patients, mean 168.7 (range 40-373) kU/L, and without significant differences between the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A positive linear relationship (r=0.61, p=0.04) could be found between AFP level and age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpha-fetoprotein in variant A-T and its relation to severity
“Mean serum AFP was 176 μg/l (range, 2–600; SD, 146) in 45 individuals with a result available. Three (6.6%) had levels in the normal range” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although AFP is considered a reliable diagnostic biomarker for the disease, in a small proportion of variant A-T patients, AFP can be normal” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, there is no clear association of AFP levels with disease severity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory abnormalities supporting the diagnosis
ATM protein and kinase activity assays
“The diagnosis of A-T can be confirmed by the absence or deficiency of ATM protein and/or ATM kinase activity in cultured cell lines established from lymphocytes or skin biopsies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These more specialized tests are not always needed, but are particularly helpful if an individual’s symptoms are atypical.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Newborn screening by T-cell receptor excision circles: proportion of classic A-T detected
“Of 13 older AT patients for whom newborn DBS had been stored, 7 samples tested positive for SCID under the criteria of California’s newborn screening program.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the fact that 24/31 (77.4%) of retrospectively analyzed newborn screening cards of patients with AT were below the cutoff values for an abnormal SCID screening result, we expect that the number of screening-identified AT cases will continue to increase as SCID newborn screening programs expand globally.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To date, 15 newborns with an early diagnosis of AT identified after SCID newborn screening have been published” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AT is not a target disease in NBS programs. Additionally, since the screening is not designed to detect AT, not all patients with AT will be identified through NBS-SCID.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Newborn screening: cases identified in the Ontario program
“Four patients were diagnosed with AT as a result of low TRECs on NBS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One case was identified per year, while the total rate for SCID has been five new cases per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parent views on diagnosis in the neonatal phase
“Twenty-six (74%) parents felt that the advantages of an early diagnosis outweighed the disadvantages, five parents thought that the disadvantages would outweigh the advantages (14%), and four parents did not indicate a preference.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay and misdiagnosis: United States referral center
“In 48 patients with AT, who were the index cases in their respective families, the median age of diagnosis (78 months) occurred after the onset of gait abnormalities (15 months) and closely corresponded to the development of telangiectasia (72 months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common misdiagnosis was cerebral palsy (29/48 cases).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend the use of routine serum alpha-fetoprotein testing for all children with persistent ataxia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay: United Kingdom national pediatric clinic
“At presentation, 71 children (90%) had ataxia. The median presentation delay (from first parental concern to presentation) was 8 months (range 0-118 months), and the median diagnostic delay (genetic confirmation of diagnosis) was 12 months (range 1-109 months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis in published cases
| Group | Median (IQR, range) age at diagnosis in months |
|---|---|
| All cases, 329 cases | “72.0 (36.0–120.0, 0.7–720.0)”View highlighted excerpt for this quote |
| Variant cases only, 14 cases | “354.0 (231.0–456.0, 24.0–720.0)”View highlighted excerpt for this quote |
| Classical cases only, 315 cases | “72.0 (36.0–108.0, 0.7–528.0)”View highlighted excerpt for this quote |
Diagnostic delay in variant A-T
“There was a diagnostic delay of more than 10 years in 68% and more than 20 years in one third of probands.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“our data suggest the condition may sometimes be mis‐ or underdiagnosed because of atypical features, including exclusive extrapyramidal symptoms, normal eye movements, and normal alpha‐fetoprotein levels in some individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with variant A-T were only correctly diagnosed in adulthood.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Measurement of serum alpha-fetoprotein and chromosomal instability precipitates the correct diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Presenting symptoms
“1314 cases reported 2134 presenting symptoms. The most common presenting symptom was abnormal gait (1160 cases; 188 studies) followed by recurrent infections in classical ataxia-telangiectasia and movement disorders in variant ataxia-telangiectasia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As expected, cerebellar gait ataxia was the most reported first presenting symptom however over a quarter did not have ataxia as their first clinical presentation. Dysarthria was reported as the first presentation in 9% of cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initial manifestations of Ataxia-telangiectasia include cerebellar symptoms (67%), dystonia (18%), choreoathetosis (10%), and tremor (4%), with parkinsonism and myoclonus not reported as initial features.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Motor symptoms: cerebellar ataxia of gait, trunk, and limbs
Neurological signs in a British Isles cohort of 70 individuals
“The majority (43/68) presented by 3 years of age with truncal ataxia. All had progressive, handicapping neurological symptoms exhibiting ataxia (70/70), ocular motor apraxia (70/70), an impassive face (70/70), dysarthria (70/70), chorea (68/70), dystonia (55/70) and peripheral neuropathy (50/70).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical immune deficiency was present in 43 of 70 patients. Ocular telangiectasia were seen in all but one case and excessive thinness in 54 of 70.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Motor symptoms: extrapyramidal movement disorders
“The prevalence of movement disorders during the course of the disease includes cerebellar symptoms (96%), dystonia (89%), parkinsonism (41%), choreoathetosis (89%), myoclonus (92%), and tremor (74%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Peripheral nervous system symptoms: sensorimotor neuropathy
“In this prospective study, 42 classical A-T patients were assessed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We found significant correlations between age and the development of motor and sensory polyneuropathy in A-T compared with healthy controls (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oculomotor symptoms: oculomotor apraxia, saccade abnormalities, and nystagmus
“Abnormal eye movements associated with A-T include: oculomotor apraxia, nystagmus (including horizontal nystagmus in primary gaze, nystagmus on lateral gaze, post-rotary nystagmus and periodic alternating nystagmus), hypometric saccades and saccadic intrusions, convergence/accommodation and VOR abnormalities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Visual acuity was preserved in most patients, with 24 (79%) achieving 6/12 or better.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eye movement recordings revealed hypometric saccades, increased latency, impaired smooth pursuit (especially vertical) and frequent nystagmus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bulbar symptoms: dysarthria
Bulbar symptoms: dysphagia and aspiration
“Seventy patients (mean age, 10.7 years; range, 1.8 to 30 years) had feeding/swallowing and nutritional evaluations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen of the 51 patients (27%) with histories suggestive of dysphagia demonstrated aspiration. Of these, silent aspiration (aspiration without a cough) occurred in 10 (71%) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aspirators were significantly older than non-aspirators (mean age, 16.9 vs 10.8 years; P =.002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Dysphagia is common in A-T and typically appears during the second decade of life because of the neurological changes which interfere with the coordination of mouth and pharynx movements necessary for safe and efficient swallowing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular and cutaneous signs: telangiectasia
“Telangiectasia within the bulbar conjunctiva over the exposed sclera of the eyes usually occur by the age of 5–8 years, but sometimes later or not at all” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The absence of telangiectasia does not exclude the diagnosis of A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunological symptoms: immunodeficiency and infections
“Immunoglobulin (Ig) deficiencies are common, affecting IgG4 in 65% of patients, IgA in 63%, IgG2 in 48%, IgE in 23%, and IgG in 18%. Lymphopenia affected 71% of patients, with reduced B-lymphocyte number in 75%, CD4 T lymphocytes in 69%, and CD8 T lymphocytes in 51%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrent upper and lower respiratory tract infections were frequent: otitis media in 46% of patients, sinusitis in 27%, bronchitis in 19%, and pneumonia in 15%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In spite of the high prevalence of laboratory immunologic abnormalities, systemic bacterial, severe viral, and opportunistic infections are uncommon in A-T.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“IgA deficiency was observed in 60.8% of patients and IgG deficiency in 28.6%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Infections were reported in the majority of the cohort (88%; 61/69).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study we analyse the clinical history and immunological data in 44 patients with A-T who attended the National Ataxia-Telangiectasia clinic in Nottingham between 2001 and 2011.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in general, for the majority of patients the severity of immune deficiency (both clinically and in terms of immunological blood markers) does not seem to deteriorate significantly with time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory symptoms: lung disease phenotypes
“There are three recognised major lung disease phenotypes. 1) Immune dysfunction leading to recurrent upper and lower respiratory tract infections (RTIs), which in turn can lead to bronchiectasis; 2) lung disease associated with dysfunctional swallow and inefficient cough due to neurodegenerative deficits, which increases the risk for aspiration and consequently may also cause or worsen bronchiectasis; and 3) ILD/pulmonary fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lingering cough, chest congestion and/or wheeze may be early symptoms of underlying lung disease in a person with A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with A-T showed significant differences compared to healthy controls in symptom score, daytime and nighttime cough, days with symptoms and missed days in kindergarten/school. Severe infections with hospitalization occurred rarely.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignancy: tumor types in children and adults
Endocrine and growth abnormalities
“We found that classic A-T patients were smaller overall, and suffered from height and weight faltering that continued throughout childhood and adolescence. When compared to the CDC growth references, the median heights and weights for both male and female patients eventually fell to or below the 3rd centile on the CDC charts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive symptoms
“Cognitive deficits in AT at a young age are mild and limited to visual-spatial functions. More widespread cognitive difficulties emerge with age and disease progression, impacting executive function, spatial skills, affect, and social cognition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Radiosensitivity
“People with A-T have an increased sensitivity to ionizing radiation (X-rays and gamma rays), which can be cytotoxic. X-ray exposure should be limited to times when it is medically necessary for diagnostic purposes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Presentation of variant A-T
“Only one third had predominant ataxia, and 18% had a pure extrapyramidal presentation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no significant respiratory or immunological complications, but 25% of individuals had a history of malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Cancer incidence: French national registry
“In this large retrospective cohort, 69 patients with cancers (24.5%) were identified among 279 patients with AT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight patients developed acute leukemias (including four T-cell acute lymphoblastic leukemias), 12 developed Hodgkin lymphoma (HL), 38 developed non-Hodgkin lymphoma (NHL), three developed T-cell prolymphocytic leukemia (T-PLL), and eight developed carcinoma at a median age of 8.3, 10.6, 9.7, 24.2, and 31.4 years, respectively (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Immunodeficiency was associated with increased risk of cancer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cancer incidence: Johns Hopkins Ataxia Telangiectasia Clinical Center cohort
“Eighty-four (16.5%) of 508 individuals were diagnosed with a primary cancer, of whom 62 (74%) were hematologic in origin and 22 (26%) were solid-organ cancers. The cumulative incidence of cancer was 29% by age 35 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non–Hodgkin lymphoma occurred most frequently (n = 39), whereas solid cancers disproportionately affected those 18 years and older (n = 22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Childhood cancer risk: German register-based cohort
“Among the 160 patients with AT, we observed 19 cases of childhood cancer (15 cases of lymphoma, three cases of leukemia, and one case of medulloblastoma) versus 0.32 expected. This corresponds to a 56-fold increased risk (SIR = 56; 95% CI, 33 to 88).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 11% of patients with FA and 14% of patients with AT develop cancer by age 18 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor type, residual ATM kinase activity, and breast cancer risk
“From a total of 296 consecutive genetically confirmed A-T patients from the British Isles and the Netherlands, we identified 66 patients who developed a malignant tumour; 47 lymphoid tumours and 19 non-lymphoid tumours were diagnosed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part of the A-T phenotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This gives a standardised mortality ratio of 31.1 (with a wide 95% CI=14.4–74.7) equivalent to a cumulative risk of breast cancer diagnosis by the age of 50 years of 45% (95% CI=24–76%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes of hematological malignancies in children and young adults
“In this multinational, observational study we report 202 patients aged ≤25 years with A-T and hematological malignancies from 25 countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four-year overall survival and event-free survival (EFS) were 50.8% (95% confidence interval [CI], 43.6-59.1) and 47.9% (95% CI 40.8-56.2), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The major cause of treatment failure was treatment-related mortality (TRM) with a four-year cumulative incidence of 25.9% (95% CI, 19.5-32.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess cancer incidence in a historical United States cohort
Cancer in variant A-T
“Fourteen patients have been diagnosed with a malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Missense mutations were associated with milder neurological disease severity, but with a higher risk of malignancy, compared to leaky splice site mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic lung disease: bronchiectasis and interstitial lung disease
“The medical records of 97 patients with A-T and chronic lung disease were reviewed. Interstitial lung disease (ILD) was specifically diagnosed in 25 of 97 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen of these 25 patients with ILD died within 24 months of the onset of their ILD, and of 7 patients treated with corticosteroids, 5 are still alive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Occurrence of recurrent sinopulmonary infections (n=45) and bronchiectasis (n=22) were found to be more common in patients with impaired immunological parameters (P=0.029 and P=0.023, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lung disease is common in patients with A-T and often progresses with age and neurological decline. Diseases of the respiratory system cause significant morbidity and are a frequent cause of death in the A-T population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lung function
“The mean forced vital capacity % predicted (FVC %) in the population was 56.6 ± 20.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant change in FVC % was found in a subset of subjects (n = 25) who underwent pulmonary function testing on two or more occasions over an average of 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dysphagia, growth failure, and nutritional decline
“Oropharyngeal dysphagia is common and appears to be progressive in patients with ataxia-telangiectasia. Older patients also have a higher incidence of poorer nutritional status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“101 children (51 girls) had 222 measurements (32 once, 32 twice, 24 thrice) between 2009 and 2016.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“35/101 children had weight Z-scores below -2 on at least one occasion. Weight, height and BMI Z-scores declined over time. Decline was most obvious after 8 years of age. 14/101 (14%) children had a PEG, with longitudinal data available for 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The distribution of patients according to nutritional status by age group revealed an over-time increase in the proportion of patients with severe thinness (p = 0.016). High glucose and triglyceride levels were observed in 9.5% and 23.6% of patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes and insulin resistance
“Seven out of 39 (17.9%) patients suffered from diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diabetes is a common finding in older A-T patients and often starts in puberty.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver disease
“For analysis, patients were divided into two age groups (Group 1: <12 years; group 2: ≥12 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultrasound revealed hepatic steatosis in 11/19 (57.9%) patients in group 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver disease is present in the majority of older A-T patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loss of ambulation, neuropathy, and immobility
“Polyneuropathy, determined by clinical examination was present in 9/13 (69%) and by neurophysiological studies in 3/5 (60%), cognitive impairment in 8/14 (53%), wheelchair use in 11/14 (79%), and cerebellar atrophy in 9/11 (82%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients with classic A–T beyond the age of 30 years were wheelchair-bound and dependent on others in activities of daily living (ADL). As a result of immobilization most patients developed pressure sores and had constipation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Orthopedic and age-related complications
“Acquired deformity of the feet is common in people with A-T (unpublished observations) and compounds the difficulty individuals have with walking due to impaired coordination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Certain problems occur with an unexpectedly high frequency in patients with A-T who survive into their twenties and beyond.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Ataxia-telangiectasia
Humanistic burden and health-related quality of life
PedsQL study in children and young people: design and population
PedsQL study in children and young people: total scores compared with healthy controls
| Rater | Ataxia-telangiectasia | Healthy controls | p value |
|---|---|---|---|
| Child or young person, total QoL | “53.8 ± 12.6” | “81.8 ± 11.8” | “<.0005” |
| Parent proxy, total QoL | “43.2 ± 13.2” | “90.7 ± 8.7” | “<.0005” |
PedsQL study in children and young people: self-report, parent proxy report, age, and neurological disability
PedsQL study in children and young people: limitations stated by the authors
PROMIS survey of adult and pediatric participants and caregivers
“PRO evaluations of 90 international adult and pediatric A-T patients and their caregivers were completed via secure online administration of Patient-Reported Outcomes Measurement Information System (PROMIS) short forms evaluating anger, cognition, mood, social health, fatigue, pain, anxiety, and upper extremity function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It was found that a diagnosis of A-T complexly impacts patient PROs, but such data offers the potential for preventative and therapeutic interventions to improve the care of such patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While most A-T patients and their caregivers feel their primary A-T medical provider has expertise and compassion in addition to being accessible and trustworthy, a significant percentage of study subjects did not agree that their provider was an expert in A-T or overall trustworthy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Interviews with young people aged 16 to 27 years: study population
Interviews with young people aged 16 to 27 years: loss of walking, tiredness, and speech
Interviews with young people aged 16 to 27 years: mental health and sources of emotional support
Fatigue, social isolation, and mental health in older children and adolescents
“Children and adolescents with A-T often complain of progressive daily fatigue which can be exacerbated by physical activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Quality of life may deteriorate in older children and adolescents due to their increasing disabilities, social isolation, and the development of depression and anxiety. Attention to mental health care needs should be given to all children and adults with A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dependence in activities of daily living among adults older than 30 years with classic disease
“All patients with classic A–T beyond the age of 30 years were wheelchair-bound and dependent on others in activities of daily living (ADL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All Dutch patients were unable to write, type, or use a phone. All patients needed help with feeding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although validated questionnaires to assess quality of life were not used by us, nor was this explicitly scored in any of the patients from the literature, we believe this is poor in older patients with A–T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Cost-of-illness and claims-based studies specific to ataxia-telangiectasia
No evidence found.
Cost of illness of inherited ataxia in Ireland: a cohort that included 4 participants with ataxia-telangiectasia
“One hundred twenty-nine respondents completed a cross-sectional study on healthcare resource utilisation for progressive ataxia in Ireland. Costs were calculated using a prevalence-based approach and bottom-up methodology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the remaining 129, 56 (43%) had FRDA and 18 (14%) had a different type of inherited ataxia (Non-FRDA): these included ataxia-telangiectasia (n = 4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The COI for inherited ataxia in 2016 was €59,993 per person per year. Results were similar between participants with Friedreich’s ataxia (FRDA, n = 56), non-FRDA (n = 18) and those with undetermined ataxia (n = 55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indirect costs, based on productivity losses by participants or caregivers, accounted for 52% of the cost of illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over two thirds of participants required professional or informal homecare and used a wheelchair.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intensive care admissions at one academic center, 1995 to 2009
“Seven consecutive patients with confirmed diagnosis of ataxia-telangiectasia had nine intensive care admissions between January 1995 and December 2009.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean duration of intensive care unit stay was 17 days (median, 9 days; range, 2-39 days). The most common admitting diagnosis was respiratory distress (six of seven patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-three percent (three of seven patients) survived to intensive care unit discharge with a 3-yr survival that was 14% (one of seven patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hospital visits and admissions as a disruption to schooling
Economic impact of Ataxia-telangiectasia on families
Household income and parental employment
Cost of mobility equipment and other one-off purchases
Productivity losses and informal care in inherited ataxia: a cohort that included 4 participants with ataxia-telangiectasia
“Disability associated with inherited ataxia is incapacitating; almost half of participants reported being unable to work or retiring due to their illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While various financial supports from the state subsidise the indirect costs from productivity losses, almost 75% of these societal costs still fall to patients and caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Cost of diagnostic testing specific to ataxia-telangiectasia
No evidence found.
Molecular genetic testing that establishes the diagnosis
Diagnostic confirmation required for entry to the pivotal trial
Sequential genetic testing in inherited ataxia
“These investigations and the associated clinic visits incur substantial costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, patients requiring genetic testing often undergo sequential testing for multiple genes or costly next-generation sequencing before a diagnosis is identified [9].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delay between symptom onset and diagnosis
“All 13 AT patients initially presented with symptoms of ataxia and abnormal gait between ages 12 months and 8 years (median 17 months). Patients experienced a delay from 2 months to 10 years between onset of symptoms and AT diagnosis, which occurred between ages 1.5 and 12 years (median age 3 years 5 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the experience of our national reference center for A-T at the Radboud University Medical Center, we know that the diagnostic process for A-T may take a long time and may include many procedures, e.g., lumbar punctures, muscle biopsies, and diagnostic x-rays (which are potentially harmful in the context of a DNA-repair disorder).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Yield of newborn screening for severe combined immunodeficiency
“Of 13 older AT patients for whom newborn DBS had been stored, 7 samples tested positive for SCID under the criteria of California’s newborn screening program.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four patients were diagnosed with AT as a result of low TRECs on NBS. In each case, whole exome sequencing was diagnostic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One case was identified per year, while the total rate for SCID has been five new cases per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Views of parents of healthy newborns on early detection, additional tests, hospital visits, and health costs
“A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Views of parents of affected children on early diagnosis
“Twenty-six (74%) parents felt that the advantages of an early diagnosis outweighed the disadvantages, five parents thought that the disadvantages would outweigh the advantages (14%), and four parents did not indicate a preference.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of parents of a child with A-T would have preferred an early diagnosis during the asymptomatic phase of the disease, because the uncertainty during the diagnostic process had had a major impact on their lives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antenatal diagnosis and carrier detection within affected families
Approaches to treatment
Current treatment options and standard of care
Multidisciplinary supportive care
Guideline scope and recommendation for multidisciplinary symptomatic treatment
Supportive care and the specialties involved
Manifestations that respond to treatment and those that do not
“The management and treatment of A-T is symptomatic and supportive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment of the neurologic problems associated with A-T is symptomatic and supportive, as there are no treatments known to slow or stop the neurodegeneration. However, other manifestations of A-T, e.g. immunodeficiency, pulmonary disease, failure to thrive and diabetes can be treated effectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Status of the United Kingdom clinical guidance for children
Effect of supportive and multidisciplinary care on survival and quality of life
Physical, occupational, and speech therapy
Guideline position on rehabilitation therapy
Expected effect of therapy and exercise on function and on neurodegeneration
“Physical, occupational and speech therapies as well as exercise may help maintain function but will not slow the course of neurodegeneration. Therapeutic exercises should not be used to the point of fatigue and should not interfere with activities of daily life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Roles of physical therapists and speech-language therapists
Physiotherapy aims and postural management in children
Scoping review of nursing and allied health interventions: strength of the evidence
“Although limited, some of the evidence included within this review was specific to A-T and may, therefore, hold direct relevance to our research question: most notably, therapeutic exercise, including coordinative training, IMT, and early nutritional intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, this review makes evidence-guided rather than evidence-based recommendations for practice given the lack of rigorous research focused on children and young people with A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptomatic medications for ataxia and movement disorders
Guideline position on drug treatment of ataxia, dystonia, and chorea
Effectiveness of pharmacotherapy for extrapyramidal movement disorders
Drugs commonly prescribed for neurological symptoms
“Commonly prescribed drugs include trihexyphenidyl (Artane), amantadine [148], baclofen and BOTOX® injections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, to date, their efficacy and the features of motor impairment that would best be targeted in A-T are not known. All drugs should be prescribed by a neurologist familiar with the assessment and treatment of individuals with movement disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amantadine: open-label study in 17 children
“We treated 17 children (aged 11.2 ± 3.9 years) for 8 weeks with the dopaminergic and anti-N-methyl-d-aspartate (NMDA) agent amantadine sulfate 6.3 ± 0.87 mg/kg/d.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 76.5% of patients were responders, with a mean 29.3% improvement. Ataxia, involuntary movements, and parkinsonism improved significantly (25.3%, 32.5%, and 29.5%, respectively); (P < .001, t test).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Side effects were mild and transient, and they did not lead to drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Assessment of long-term effects and a double-blind study should follow.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Amantadine: appraisal in a systematic review
“However, the composite AT score, aggregating ICARS, the Abnormal Involuntary Movement Scale, and the Unified Parkinson's Disease Rating Scale, may primarily reflect effects on parkinsonian symptoms rather than direct improvement in cerebellar ataxia, and the absence of a control group, small sample size (n = 17), and short follow‐up duration severely limit the interpretability of these findings [30].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
4-Aminopyridine: eye movement and vestibular function in 4 participants
“The influence of 4-AP on disorders of eye movements and vestibular function was studied in four A-T patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among two A-T subjects who manifested PAN, 4-AP reduced the peak slow phase velocity of the more severely affected individual and abrogated the PAN in the other.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nicotinamide riboside: guideline statement
Nicotinamide riboside: open-label study over 4 months
“In this open‐label, proof‐of‐concept study, 24 patients with A‐T were treated with NR during four consecutive months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During treatment, ataxia scores improved; mean total Scale for the Assessment and Rating of Ataxia and International Cooperative Ataxia Rating Scale scores decreased to 2.4 and 10.1 points, respectively. After NR withdrawal, ataxia scores worsened.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse effects did not occur.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nicotinamide riboside: open-label study over 2 years
“A single-arm, open-label clinical trial was performed in individuals with A-T, receiving NR over a period of 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total scores in the neuromotor test panels, as evaluated at the 18-month time point, improved for all but one participant, primarily driven by improvements in coordination subscores and eye movements.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Triheptanoin: phase 2a/b placebo-controlled dose-escalation trial
“31 participants with A-T were enrolled aged from 4 to 37 years (median 16-years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome was cell death in respiratory epithelial cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events including abdominal pain, nausea, vomiting, and diarrhoea, requiring dose capping at 20%, were observed in 12 (38%) participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroids
Guideline position on steroids for ataxia
Oral betamethasone: randomized crossover trial in 13 children
“In a multicenter, double-blind, randomized, placebo-controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this study of 13 A-T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (ie, median percent decreases of ataxia symptoms of 28% and 31%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, Oral betamethasone could be a promising therapy to relieve ataxia symptoms in A-T patients; however, long-term effectiveness and safety must be established.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral betamethasone: minimum effective dose in 9 participants
“Nine A-T patients were enrolled to receive betamethasone at increasing dosages of 0.001, 0.005 and 0.01 mg/kg/day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Four of nine patients had a benefit at a dose of 0.005 mg/kg/day of oral betamethasone. Using the higher dosage, only one additional patient had a positive response. Conversely, a daily dose of 0.001 mg/kg was ineffective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral betamethasone: two years of treatment in 6 participants
“Six patients with ataxia telangiectasia received betamethasone at 0.02 mg/kg/day for two years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Transient improvement of neurological symptom was observed in five of the six patients. However, after two years betamethasone treatment, only one of the six patients showed a slight improvement in the neurological score, one patient showed no change, and the neurological scores of the remaining four patients deteriorated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As an adverse effect of betamethasone, transient adrenal dysfunction was observed in all cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: phase 2 open-label trial
“Twenty two patients (F:M = 1; mean age 11.2 ± 3.5) with a confirmed diagnosis of AT and a preserved or partially supported gait were enrolled for the study. The subjects underwent for six months a monthly infusion of EryDex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An improvement in ICARS (reduction of the score) was detected in the intention-to-treat (ITT) population (n = 22; p = 0.02) as well as in patients completing the study (per protocol PP) (n = 18; p = 0.01), with a mean reduction of 4 points (ITT) or 5.2 points (PP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: 24-month extension in 4 participants
“After the end of the first trial, 4 patients continued to be treated with monthly EryDex infusions for an additional 24 months, and their clinical outcome was compared with that of 7 age-matched patients who stopped the treatment after the first 6 infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These promising preliminary results call for a large-scale controlled study on protracted treatment of patients with AT with dexamethasone-loaded erythrocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: ATTeST phase 3 trial design and population
“This multicentre, randomised, double-blind, placebo-controlled, phase 3 trial was done at 22 centres in 12 countries (Australia, Belgium, Germany, India, Israel, Italy, Norway, Poland, Spain, Tunisia, the UK, and the USA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible participants were children aged 6 years or older weighing more than 15 kg who met clinical criteria for ataxia telangiectasia but who had preserved autonomous gait.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“175 patients received at least one dose of treatment (59 patients received the low dose and 57 received the high dose of intra-erythrocyte dexamethasone sodium phosphate, and 59 received placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: ATTeST phase 3 trial primary endpoint
“Compared with the placebo group, no differences were identified with regard to change in mICARS score from baseline to 6 months in the low-dose group (least squares mean difference -1·37 [95% CI -2·932 to 0·190]) or the high-dose group (-1·40 [-2·957 to 0·152]; p=0·0765).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although there were no safety concerns, the primary efficacy endpoint was not met, possibly related to delays in treatment reducing the number of participants who received treatment as outlined in the protocol, and potentially different treatment effects according to age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: NEAT phase 3 trial design and population
“NEAT was a multicentre, randomised, double-blind, placebo-controlled phase 3 study, conducted at 20 sites across nine countries (Denmark, Germany, Italy, Norway, Poland, Spain, Switzerland, UK, and USA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between June 24, 2024, and Dec 17, 2025, we screened 125 participants for eligibility, of whom 105 (84%) were randomly assigned to the eDSP group (n=51 [49%]) or the placebo group (n=54 [51%]) and received at least one dose of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: NEAT phase 3 trial primary endpoint
“Compared with the placebo group, no significant differences were identified in change in RmICARS score from baseline to 6 months in participants aged 6-9 years: least squares mean difference -1·30 (95% CI -2·77 to 0·18; p=0·085).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary efficacy endpoint was not achieved, because the effect of eDSP on neurological symptoms did not reach statistical significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone: development status
Intra-erythrocyte dexamethasone: safety over at least 2 years of treatment
“Sixty-eight patients completed a minimum of 2 years of treatment with EryDex (mean treatment length 39 ± 11 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notable adverse events included transient pruritus reported in 23 (34%) patients and findings of low serum iron reported in 27 (40%) patients, while at baseline one fifth of patients had low serum iron.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean bone mineral density (BMD) z-score showed a decline of 0.4 points over the 24 months of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunoglobulin replacement and infection prophylaxis
Guideline indications for immunoglobulin replacement
“Immune replacement therapy is considered when hypogammaglobulinemia and/or specific antibody deficiency is present together with a history of recurrent respiratory infections or established bronchiectasis, or when other preventive measures such as vaccinations and prophylactic antibiotics do not result in clinical improvement of the RTI symptoms irrespective of the severity of the immunological abnormalities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of patients who receive immunoglobulin replacement
“Hence there is wide variation in the proportion of patients who are on replacement treatment (table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If Ig therapy is considered, most centres administer subcutaneous Ig, as is currently recommended for severe immundeficiencies [29–31].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Retrospective series | Receiving immunoglobulin therapy (%) |
|---|---|
| 80 participants | “12.5”View highlighted excerpt for this quote |
| 100 participants | “13”View highlighted excerpt for this quote |
| 15 participants | “60”View highlighted excerpt for this quote |
| 240 participants | “34.8”View highlighted excerpt for this quote |
| 44 participants | “15.9”View highlighted excerpt for this quote |
| 100 participants | “18.8”View highlighted excerpt for this quote |
Evidence base for prophylactic antibiotics and immunoglobulin replacement
“No placebo-controlled trials have been performed with regards to prophylactic antibiotic therapy or immune replacement therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high proportion (74%) of children with A-T are prescribed prophylactic antibiotics [24] on inconsistent and non-evidence-based criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline position on prophylactic antibiotics
“Prophylactic antibiotic treatment is considered when the burden of respiratory infections is high, if there is associated specific polysaccharide antibody deficiency and when there is established bronchiectasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory care
Evidence base for respiratory management
“There are no randomised controlled trials with respect to the treatment of the respiratory complications in A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current approaches are based on minimal best available evidence in A-T, and extrapolation from other more common disorders such as cystic fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lung function monitoring
“Regular assessments at least twice a year provide an impression of the degree of lung decline and allows for proactive early intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Children with A-T should undergo annual lung function studies starting at 6 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These interventions may include the initiation of a cough assist device and chest physiotherapy to help improve MCC and lung inflation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibiotic treatment of respiratory symptoms
“Administration of antibiotics should be considered when children and adults have prolonged respiratory symptoms (greater than 7 days) following a respiratory illness, including those that begin with a viral illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interstitial lung disease
“Progressive, diffuse lung disease that poorly responds to aggressive antibiotic therapy, physiotherapy and immunoglobulin replacement and to which aspiration does not seem to contribute should lead to consideration of noninfective causes of lung disease in A-T, including ILD and pulmonary fibrosis and early treatment with corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inspiratory muscle training: study in 11 participants
“A longitudinal study was conducted with 11 AT patients and nine healthy volunteers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The health and vitality domains of the SF-36 also showed significant improvement (P = 0.009 and P = 0.014, respectively) post-IMT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nutritional support and gastrostomy
Guideline recommendations on feeding support and gastrostomy
“Assessment of the adequacy and safety of nutritional intake should be performed at least annually. Provision of supplemental calories by the oral or enteral route should be undertaken in those with worsening nutritional status. Early gastrostomy insertion is likely to be required in those with unsafe swallow or inadequate nutritional intake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indications for a gastrostomy tube
“A gastrostomy tube (G-tube or feeding tube) is recommended when any of the following occur: a child cannot eat enough to grow or a person of any age cannot eat enough to maintain weight; aspiration is problematic; mealtimes are stressful or too long, interfering with other activities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrostomy at the Johns Hopkins clinic: tolerance and caregiver satisfaction
“We completed a retrospective review of 175 patients who visited the A-T Children's Center at Johns Hopkins Hospital from 2001 through 2008, and identified 28 patients with A-T (19 males, 9 females) who underwent GT placement for non-palliative reasons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five (89%) patients tolerated GT placement and were a median of 5.0 (0.4-12.6) years post GT placement at the time of this investigation. Three (11%) patients died within one month of GT placement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In comparison to patients who tolerated GT placement, patients with early mortality were older when GT's were placed (median 24.9 vs. 12.3 years, p = 0.006) and had developed a combination of dysphagia, nutritional, and respiratory problems.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers of patients tolerating GT placement reported significant improvements in mealtime satisfaction and participation in daily activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gastrostomy at the United Kingdom national pediatric clinic
“14/101 (14%) children had a PEG, with longitudinal data available for 12. In a nested case control study, there was a trend for improvement in weight in those with a PEG (p=0.10).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest early proactive consideration of PEG from age 8 years onwards to prevent progressive growth failure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gastrostomy in a single-center cohort followed from 1986 to 2015
Caregiver acceptance of gastrostomy
“We know how to manage the nutritional needs of people with A-T, but do not do an adequate job of communicating this to caregivers and convincing them to use gastrostomy tubes to deliver supplemental calories early enough in life to make a difference to their children.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Before the approval of levacetylleucine in September 2026, no therapy was approved for ataxia-telangiectasia in any market, and no treatment was known to slow or stop the neurological decline. Published guidance rests on expert opinion and small non-randomized studies: the European Respiratory Society statement reports no randomized controlled trials of respiratory treatments and no placebo-controlled trials of prophylactic antibiotics or immunoglobulin replacement, and the United Kingdom guidance for children states that it is not an evidence-based guideline. Evidence for symptomatic drugs comes from open-label studies of amantadine (17 participants, 8 weeks), 4-aminopyridine (4 participants), and nicotinamide riboside (24 participants, 4 months). Oral betamethasone reduced the ICARS total score by a median of 13 points in a crossover trial of 13 participants; in a two-year study of 6 participants, the neurological scores of 4 participants deteriorated and all 6 had transient adrenal dysfunction. Intra-erythrocyte dexamethasone did not meet its primary endpoint in the ATTeST trial (175 participants treated) or in the NEAT trial (105 participants), and its sponsor ceased clinical development in January 2026. A 2026 systematic review of 13 studies with 314 participants concluded that no intervention had demonstrated sustained efficacy in adequately powered controlled trials. Physical, occupational, and speech therapies may maintain function and do not slow neurodegeneration.
Absence of a treatment that slows neurological decline
“There is no treatment known to slow or stop the progression of the neurologic deficits associated with A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although physical and occupational therapies and exercise may help maintain overall physical well-being and quality of life, there are currently no treatments capable of slowing or halting the neurologic decline in A-T.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of pharmacological treatment of ataxia in pediatric ataxia-telangiectasia
“Thirteen studies (3 RCTs, 10 single‐arm trials) involving 314 participants (mean age 10.87 years) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No intervention has demonstrated sustained efficacy in adequately powered controlled trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recurrent pattern of promising open‐label findings followed by negative phase 3 results highlights a translational gap attributable to methodological limitations, including small sample sizes, heterogeneous populations, and variable outcome measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current evidence remains insufficient to guide clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of an approved therapy before September 2026
“To date, there are no approved treatments for ataxia-telangiectasia anywhere.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ataxia telangiectasia is a rare, multisystem disorder with progressive cerebellar neurodegeneration and no approved treatments. The efficacy of corticosteroids, including erythrocyte encapsulated dexamethasone sodium phosphate (eDSP), which have been studied for two decades in this disease, has not yet been proven in randomised trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
Levacetylleucine was approved in the United States in September 2026 for ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, and the FDA describes it as the first treatment approved for ataxia in this disease. The indication is defined by diagnosis and body weight, and the label lists no contraindications. The pivotal trial enrolled 73 participants aged 4 years or older with genetically confirmed disease and a SARA score of 7 to 34; participants younger than 4 years, asymptomatic participants, and participants with advanced disease who could not complete functional assessments were excluded. The trial authors propose levacetylleucine as a first-line, foundational therapy. Dosing follows body weight (2 g, 3 g, or 4 g per day in two or three doses) as an oral suspension taken with or without food or given through a gastrostomy tube, and the label directs patients and caregivers to the Instructions for Use. The approved indication covers ataxia; published guidance continues to recommend multidisciplinary supportive care for immunodeficiency, respiratory disease, nutrition, and malignancy surveillance. Pregnancy status is verified before initiation in females of reproductive potential, and concomitant N-acetyl-DL-leucine and N-acetyl-D-leucine are avoided. The 12-week controlled period measured a symptomatic effect that was lost during the subsequent placebo period, and long-term data depend on the ongoing open-label extension. The manufacturer stated that the product was commercially available at approval.
First treatment approved for ataxia in ataxia-telangiectasia
Position proposed by the pivotal trial investigators
“Given that ataxia-telangiectasia is a debilitating, prematurely fatal condition with no approved drug, if approved, levacetylleucine could be considered as the first-line, foundational therapy for the treatment of ataxia-telangiectasia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Population studied and populations excluded from the pivotal trial
“Eligible patients were aged 4 years or older with a genetically confirmed diagnosis of ataxia-telangiectasia; had a SARA score of 7–34 and were either within the 2–7 range of the gait subtest of the SARA scale or were able to perform the 9-hole peg test with their dominant hand in a time of 20–150 sec; and weighed 15 kg or more at screening.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Second, the focus on symptomatic endpoints excluded patients younger than 4 years, asymptomatic patients, or patients with advanced disease states who would not be reliably able to complete functional assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Route of administration and care setting
Commercial availability at approval
Heterogeneity of treatment effect
Predefined subgroup analyses of the primary endpoint in IB1001-303
“For the primary and each secondary endpoint, there were separate evaluations within key subgroups predefined in the statistical analysis plan (the trial was not powered for conclusions in these subgroups).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Figure 3B displays results for the primary SARA endpoint in the predefined subgroups showing 95% CIs. There is no evidence of heterogeneity in treatment effect across subgroups that would suggest a differential treatment effect across the population. Instead, across all subgroups, there were consistent improvements with levacetylleucine versus placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis showed consistent benefit across all demographics of patients, irrespective of age (paediatric vs adult), age at disease onset, or gender.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analyses showed that the improvement in neurological status was observed across all demographics of patients (age of neurological disease onset, disease severity, and gender, etc), indicating that the treatment might be applicable for all patients with ataxia-telangiectasia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Size of the age, age-at-diagnosis, and dose subgroups in IB1001-303
| Subgroup | Participants (n=73) |
|---|---|
| Paediatric (<18 years) | “47 (64%)”View highlighted excerpt for this quote |
| Adult (≥18 years) | “26 (36%)”View highlighted excerpt for this quote |
| Age at diagnosis: early-infantile (<2 years) | “51 (70%)”View highlighted excerpt for this quote |
| Age at diagnosis: late-infantile (2 to <6 years) | “16 (22%)”View highlighted excerpt for this quote |
| Age at diagnosis: juvenile (6 to <15 years) | “3 (4%)”View highlighted excerpt for this quote |
| Age at diagnosis: adolescent or adult (≥15 years) | “3 (4%)”View highlighted excerpt for this quote |
| Weight 15 to <25 kg (2 g per day) | “18 (25%)”View highlighted excerpt for this quote |
| Weight 25 to <35 kg (3 g per day) | “17 (23%)”View highlighted excerpt for this quote |
| Weight ≥35 kg (4 g per day) | “38 (52%)”View highlighted excerpt for this quote |
Randomization without stratification by age
Company statements on subgroup consistency
Classic versus variant ataxia-telangiectasia
No evidence found.
Pediatric, low body weight, and geriatric populations in the label
Care management intervention strategies
United Kingdom specialist center model for children
Local care between specialist center visits
National adult service specification in England
Multidisciplinary clinics in other countries
Recommended surveillance
| System or concern | Evaluation | Frequency |
|---|---|---|
| Neurologic | “Eval by neurologist for response to therapy for existing findings & development of new findings” | “Annually” |
| Immunodeficiency | “By immunologist (immunoglobulin levels, white blood cell count)” | “Annually” |
| Pulmonary disease | “Lung function testing (by spirometry)” | “Annually for persons w/evidence of disease at time of initial diagnosis” |
| Malignancy, laboratory | “Blood count & smear, immunoglobulin levels, M protein, LDH, IgM” | “Annually” |
| Malignancy, abdomen | “Ultrasound exam of abdomen in adulthood” | “Annually” |
| Malignancy, breast | “Breast MRI in females” | “Annually starting at age 25 yrs” |
| Diabetes | “Diabetes screening: urinalysis, fasting blood glucose concentration, Hgb A1c” | “Annually in adults” |
| Feeding and nutrition | “By SLP/nutritionist” | “Annually” |
Avoidance of ionizing radiation
Pregnancy testing and contraception during levacetylleucine treatment
Monitoring with concomitant P-glycoprotein substrates
Clinical scales available to document neurological status in practice
Other product development or post-marketing obligations required by the FDA
Summary: postmarketing obligations for levacetylleucine
The FDA approval letter for the A-T supplement (NDA 219132/S-002, 18 September 2026) lists no postmarketing requirement or postmarketing commitment and contains no pediatric assessment section. It requires submission of structured product labeling within 14 days, patent information within 30 days, and compliance with the reporting requirements for an approved NDA. The original approval letter of 24 September 2024 for the NPC indication set eight postmarketing requirements under section 505(o) (PMR 4683-1 to 4683-8), comprising seven nonclinical toxicology and carcinogenicity studies and one clinical drug-drug interaction trial with a P-gp probe substrate, and one postmarketing commitment (PMC 4683-9), a food effect trial. The agreed final report dates run from December 2024 to June 2029. That letter states that the application was exempt from the Pediatric Research Equity Act assessment requirement because the product has orphan drug designation for the indication. The prescribing information revised in September 2026 states that animal studies of carcinogenic potential and of fertility have not been conducted.
A-T supplement approval letter: labeling and reporting obligations
Postmarketing requirements from the 2024 approval: basis for the nonclinical studies
Postmarketing requirements from the 2024 approval: nonclinical studies
Postmarketing requirements from the 2024 approval: clinical drug-drug interaction trial
| Requirement | Trial | Trial completion | Final report submission |
|---|---|---|---|
| PMR 4683-8 | “Conduct a clinical drug-drug interaction (DDI) trial in healthy volunteers to evaluate the effect of levacetylleucine on a probe substrate of P-gp to thoroughly assess its inhibitory potential and its impact on patient safety.” | “09/2026” | “09/2027” |
Postmarketing commitment from the 2024 approval: food effect trial
| Commitment | Trial | Trial completion | Final report submission |
|---|---|---|---|
| PMC 4683-9 | “Conduct a dedicated food effect trial to evaluate the impact of food on exposure of levacetylleucine granules for oral suspension” | “09/2025” | “03/2026” |
Status of the required studies as reflected in the September 2026 prescribing information
Rare pediatric disease priority review voucher: sponsor obligations
Other product development: phase 3 trial in CACNA1A-related disorders
Ongoing post-approval monitoring
Extension phase of the pivotal A-T trial
Monitoring recommended in the prescribing information
Periodic status reports on postmarketing studies
European Union pharmacovigilance: additional monitoring
Real-world evidence collection through the specialty pharmacy
Product registry for ataxia-telangiectasia
No evidence found.
Expected outcomes of therapy
Functional SARA after 12 weeks: prescribing information
SARA total score after 12 weeks: trial publication
“The mean change in the SARA score following 12 weeks of treatment was –1·92 (SD 2·81) with levacetylleucine treatment and –0·14 (2·38) with placebo (linear mixed model treatment effect –1·88, SD 0·41; 95% CI –2·70 to –1·06; p<0·0001; table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Change from baseline on each scale after 12 weeks: trial publication
Loss of effect after crossover to placebo
“By contrast, patients who received levacetylleucine followed by placebo (n=35) had an increase in SARA score of 1·81 (SD 3·12) during period 2 on placebo, which effectively served as a washout from levacetylleucine, reflecting a deterioration in neurological signs and symptoms when treatment with levacetylleucine was stopped.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients randomly assigned to sequence 1 (levacetylleucine to placebo), the improvements of levacetylleucine treatment observed in period 1 were lost in period 2 (consistent with the drug's pharmacological and pharmacokinetic action), as patients worsened and returned to their baseline status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Participant and caregiver exit interviews
Time to effect
Minimal clinically important difference on SARA: thresholds cited in the trial publication
“for which a 1-point change has been validated as representing a clinically meaningful change in functioning (gain or loss of complex function which is relevant to the patient's everyday life)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A sample size of 46 patients was estimated to provide 80% power, at a one-sided significance level of 5%, to detect a true mean difference between groups in the SARA scores of 1·0” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Multiple studies have investigated a minimally clinically important difference on the SARA scale, ranging from 1 to 1·5 points” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the mean change on levacetylleucine and the treatment effect with levacetylleucine versus placebo are larger than all reported thresholds” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference on SARA: lysosomal storage disorder trial cohorts
“We analyzed data from three clinical trial cohorts (IB1001-201, IB1001-202, and IB1001-301) of patients with Niemann–Pick disease type C (NPC) and GM2 Gangliosidoses (Tay–Sachs and Sandhoff disease) comprising 122 patients and 703 visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the CGI-I responses and change in SARA scores, Area Under the Curve (AUC) values were 0.82, 0.71, and 0.77 for the Investigator’s, Caregiver’s, and Patient’s CGI-I respectively, indicating strong agreement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 1-point change represents a clinically meaningful transition reflecting the gain or loss of complex function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference on SARA: cerebellar ataxia exercise trial
“Sixty‐two individuals with cerebellar ataxias participated in a home‐exercise clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MCID for SARA using anchor‐based method was 1.75. The distribution‐based method and distribution‐based mapping identified a median MCID score of 1.23.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Synthesizing the methods, we recommend an MCID of 1.5 for SARA, which is slightly higher that what is currently used in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meaningful change on the functional SARA: clinician interviews in spinocerebellar ataxia
Minimal clinically important difference established in ataxia-telangiectasia
No evidence found.
Annual SARA progression in adults with ataxia-telangiectasia
“We analysed longitudinal Scale for the Assessment and Rating of Ataxia (SARA) data from the largest published adult AT cohort to date (n = 82, age > 16 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological impairment progressed with a mean SARA increase of 0.38 points/year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability beyond 12 weeks and effects on other disease features
“First, the study was designed to investigate the symptomatic effects of levacetylleucine; data from the ongoing extension phase will provide further insights into its impact on ataxia-telangiectasia disease progression and continued data on the long-term safety of levacetylleucine for ataxia-telangiectasia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the study duration was not long enough to investigate the effects of levacetylleucine on other key features of ataxia-telangiectasia, such as immunological defects and oncological risks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An ongoing open-label extension phase of this trial will investigate potential long-term, neuroprotective and disease-modifying effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote